Examples include predicting benefit from trastuzumab therapy in breast cancer by assessing HER2/neu amplification (Sauter et al, 2009) and from cetuximab in colorectal cancer by assessing K-ras mutations (Siena et al, 2009). This evidence concerns the gene ERBB2 and breast carcinoma.